Carret Asset Management LLC Invests $213,000 in Illumina, Inc. (NASDAQ:ILMN)

Carret Asset Management LLC bought a new position in shares of Illumina, Inc. (NASDAQ:ILMN) during the fourth quarter, Holdings Channel reports. The fund bought 1,594 shares of the life sciences company’s stock, valued at approximately $213,000.

A number of other institutional investors and hedge funds also recently modified their holdings of ILMN. Versant Capital Management Inc grew its holdings in shares of Illumina by 153.7% during the fourth quarter. Versant Capital Management Inc now owns 241 shares of the life sciences company’s stock valued at $32,000 after buying an additional 146 shares in the last quarter. Golden State Wealth Management LLC purchased a new position in shares of Illumina during the fourth quarter valued at $32,000. Assetmark Inc. grew its holdings in shares of Illumina by 954.8% during the fourth quarter. Assetmark Inc. now owns 327 shares of the life sciences company’s stock valued at $44,000 after buying an additional 296 shares in the last quarter. Bank Julius Baer & Co. Ltd Zurich purchased a new position in shares of Illumina during the fourth quarter valued at $45,000. Finally, TD Private Client Wealth LLC grew its holdings in shares of Illumina by 58.5% during the third quarter. TD Private Client Wealth LLC now owns 382 shares of the life sciences company’s stock valued at $50,000 after buying an additional 141 shares in the last quarter. 89.42% of the stock is owned by institutional investors and hedge funds.

Illumina Price Performance

NASDAQ ILMN opened at $85.60 on Friday. Illumina, Inc. has a twelve month low of $80.18 and a twelve month high of $156.66. The company has a debt-to-equity ratio of 0.63, a quick ratio of 1.42 and a current ratio of 1.77. The stock has a market capitalization of $13.56 billion, a PE ratio of -11.15, a P/E/G ratio of 1.60 and a beta of 1.17. The stock has a 50-day simple moving average of $113.52 and a 200 day simple moving average of $129.88.

Illumina (NASDAQ:ILMN) last posted its quarterly earnings data on Thursday, February 6th. The life sciences company reported $0.86 earnings per share for the quarter, missing the consensus estimate of $0.92 by ($0.06). Illumina had a positive return on equity of 13.37% and a negative net margin of 27.95%. Research analysts anticipate that Illumina, Inc. will post 4.51 EPS for the current year.

Analysts Set New Price Targets

A number of brokerages have commented on ILMN. Barclays restated an “underweight” rating on shares of Illumina in a research note on Tuesday. Piper Sandler boosted their target price on Illumina from $185.00 to $190.00 and gave the company an “overweight” rating in a research note on Monday, February 10th. Guggenheim lowered their target price on Illumina from $170.00 to $150.00 and set a “buy” rating on the stock in a research note on Friday, February 7th. Morgan Stanley lowered their target price on Illumina from $150.00 to $136.00 and set an “equal weight” rating on the stock in a research note on Tuesday, February 11th. Finally, Robert W. Baird lowered their target price on Illumina from $127.00 to $90.00 and set a “neutral” rating on the stock in a research note on Wednesday, March 5th. One investment analyst has rated the stock with a sell rating, ten have issued a hold rating, ten have issued a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $140.90.

About Illumina

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.